vs

Side-by-side financial comparison of Pediatrix Medical Group, Inc. (MD) and Real Brokerage Inc (REAX). Click either name above to swap in a different company.

Real Brokerage Inc is the larger business by last-quarter revenue ($568.5M vs $493.8M, roughly 1.2× Pediatrix Medical Group, Inc.). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs -0.1%, a 6.9% gap on every dollar of revenue. On growth, Real Brokerage Inc posted the faster year-over-year revenue change (52.6% vs -1.7%).

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

Anywhere Real Estate Inc., formerly Realogy, was an American real estate services firm. It operated and franchised real estate brands that provided brokerage, relocation, title, insurance, and settlement services. Brands included Better Homes and Gardens Real Estate, Century 21 Real Estate, Coldwell Banker, Corcoran Group, ERA Real Estate and Sotheby's International Realty. In 2026, the company was acquired by Compass, Inc.

MD vs REAX — Head-to-Head

Bigger by revenue
REAX
REAX
1.2× larger
REAX
$568.5M
$493.8M
MD
Growing faster (revenue YoY)
REAX
REAX
+54.3% gap
REAX
52.6%
-1.7%
MD
Higher net margin
MD
MD
6.9% more per $
MD
6.8%
-0.1%
REAX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
MD
MD
REAX
REAX
Revenue
$493.8M
$568.5M
Net Profit
$33.7M
$-447.0K
Gross Margin
7.9%
Operating Margin
9.9%
-0.1%
Net Margin
6.8%
-0.1%
Revenue YoY
-1.7%
52.6%
Net Profit YoY
10.5%
82.7%
EPS (diluted)
$0.40
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MD
MD
REAX
REAX
Q4 25
$493.8M
Q3 25
$492.9M
$568.5M
Q2 25
$468.8M
$540.7M
Q1 25
$458.4M
$354.0M
Q4 24
$502.4M
Q3 24
$511.2M
$372.5M
Q2 24
$504.3M
Q1 24
$495.1M
$200.7M
Net Profit
MD
MD
REAX
REAX
Q4 25
$33.7M
Q3 25
$71.7M
$-447.0K
Q2 25
$39.3M
$1.5M
Q1 25
$20.7M
$-5.0M
Q4 24
$30.5M
Q3 24
$19.4M
$-2.6M
Q2 24
$-153.0M
Q1 24
$4.0M
$-16.1M
Gross Margin
MD
MD
REAX
REAX
Q4 25
Q3 25
7.9%
Q2 25
8.9%
Q1 25
9.6%
Q4 24
Q3 24
8.6%
Q2 24
Q1 24
10.3%
Operating Margin
MD
MD
REAX
REAX
Q4 25
9.9%
Q3 25
13.8%
-0.1%
Q2 25
12.8%
0.3%
Q1 25
7.0%
-1.5%
Q4 24
7.8%
Q3 24
6.6%
-0.7%
Q2 24
-31.3%
Q1 24
3.2%
-7.8%
Net Margin
MD
MD
REAX
REAX
Q4 25
6.8%
Q3 25
14.5%
-0.1%
Q2 25
8.4%
0.3%
Q1 25
4.5%
-1.4%
Q4 24
6.1%
Q3 24
3.8%
-0.7%
Q2 24
-30.3%
Q1 24
0.8%
-8.0%
EPS (diluted)
MD
MD
REAX
REAX
Q4 25
$0.40
Q3 25
$0.84
$0.00
Q2 25
$0.46
$0.01
Q1 25
$0.24
$-0.02
Q4 24
$0.37
Q3 24
$0.23
$-0.01
Q2 24
$-1.84
Q1 24
$0.05
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MD
MD
REAX
REAX
Cash + ST InvestmentsLiquidity on hand
$375.2M
$38.7M
Total DebtLower is stronger
$570.5M
Stockholders' EquityBook value
$865.9M
$53.6M
Total Assets
$2.2B
$145.2M
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MD
MD
REAX
REAX
Q4 25
$375.2M
Q3 25
$340.1M
$38.7M
Q2 25
$224.7M
$49.7M
Q1 25
$99.0M
$24.7M
Q4 24
$229.9M
Q3 24
$103.8M
$22.6M
Q2 24
$19.4M
Q1 24
$8.0M
$20.1M
Total Debt
MD
MD
REAX
REAX
Q4 25
$570.5M
Q3 25
$577.2M
Q2 25
$583.9M
Q1 25
$590.5M
Q4 24
$597.1M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
MD
MD
REAX
REAX
Q4 25
$865.9M
Q3 25
$890.7M
$53.6M
Q2 25
$833.8M
$49.2M
Q1 25
$789.2M
$32.8M
Q4 24
$764.9M
Q3 24
$732.5M
$29.8M
Q2 24
$706.5M
Q1 24
$856.2M
$25.6M
Total Assets
MD
MD
REAX
REAX
Q4 25
$2.2B
Q3 25
$2.2B
$145.2M
Q2 25
$2.1B
$149.4M
Q1 25
$2.0B
$100.5M
Q4 24
$2.2B
Q3 24
$2.1B
$102.5M
Q2 24
$2.0B
Q1 24
$2.2B
Debt / Equity
MD
MD
REAX
REAX
Q4 25
0.66×
Q3 25
0.65×
Q2 25
0.70×
Q1 25
0.75×
Q4 24
0.78×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MD
MD
REAX
REAX
Operating Cash FlowLast quarter
$114.1M
$8.8M
Free Cash FlowOCF − Capex
$8.4M
FCF MarginFCF / Revenue
1.5%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
3.39×
TTM Free Cash FlowTrailing 4 quarters
$71.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MD
MD
REAX
REAX
Q4 25
$114.1M
Q3 25
$137.3M
$8.8M
Q2 25
$137.2M
$41.0M
Q1 25
$-117.5M
$15.9M
Q4 24
$133.0M
Q3 24
$91.8M
$7.2M
Q2 24
$107.0M
Q1 24
$-125.2M
$21.5M
Free Cash Flow
MD
MD
REAX
REAX
Q4 25
Q3 25
$8.4M
Q2 25
$40.8M
Q1 25
$15.7M
Q4 24
Q3 24
$6.8M
Q2 24
Q1 24
$21.4M
FCF Margin
MD
MD
REAX
REAX
Q4 25
Q3 25
1.5%
Q2 25
7.5%
Q1 25
4.4%
Q4 24
Q3 24
1.8%
Q2 24
Q1 24
10.7%
Capex Intensity
MD
MD
REAX
REAX
Q4 25
Q3 25
0.1%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
Q3 24
0.1%
Q2 24
Q1 24
0.0%
Cash Conversion
MD
MD
REAX
REAX
Q4 25
3.39×
Q3 25
1.91×
Q2 25
3.49×
27.13×
Q1 25
-5.66×
Q4 24
4.36×
Q3 24
4.72×
Q2 24
Q1 24
-31.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

REAX
REAX

Segment breakdown not available.

Related Comparisons